Patents by Inventor Minghan Wang

Minghan Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11401329
    Abstract: Anti-CD47 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, inflammatory disease, infectious disease, atherosclerosis, cardiovascular disease, metabolic disease, radiation-induced injury, and/or autoimmune disease.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: August 2, 2022
    Assignee: Phanes Therapeutics, Inc.
    Inventors: Minghan Wang, Hui Zou, Joshua Oaks, Haiqun Jia
  • Patent number: 11390679
    Abstract: Anti-LAG-3 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, an inflammatory disease, an autoimmune disease, type 1 diabetes, and/or infectious diseases.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: July 19, 2022
    Assignee: Phanes Therapeutics, Inc.
    Inventors: Minghan Wang, Hui Zou, Haiqun Jia
  • Patent number: 11365242
    Abstract: Anti-apelin antibodies and antigen-binding fragments thereof are described.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: June 21, 2022
    Assignee: Phanes Therapeutics, Inc.
    Inventors: Minghan Wang, Hui Zou, Arvin Tam
  • Publication number: 20220184127
    Abstract: Chimeric antigen receptors (CARs) specific to DLL3, vectors encoding the DLL3 CAR, recombinant host cells comprising the DLL3 CAR (CAR-Ts or CAR-NKs), and methods of using the CAR-Ts or CAR-NKs to treat a disease associated with the expression of DLL3 thereof are described.
    Type: Application
    Filed: March 30, 2020
    Publication date: June 16, 2022
    Inventors: Minghan Wang, Hui Zou, Haiqun Jia
  • Publication number: 20220184126
    Abstract: Chimeric antigen receptors (CARs) specific to CLDN18.2, vectors encoding the CLDN18.2 CAR, recombinant host cells comprising the CLDN18.2 CAR (CAR-Ts or CAR-NKs), and methods of using the CAR-Ts or CAR-NKs to treat a disease associated with the expression of CLDN18.2 thereof are described.
    Type: Application
    Filed: March 24, 2020
    Publication date: June 16, 2022
    Inventors: Minghan Wang, Hui Zou, Haiqun Jia
  • Publication number: 20220162301
    Abstract: Chimeric antigen receptors (CARs) specific to FOLR1, vectors encoding the FOLR1 CAR, recombinant host cells comprising the FOLR1 CAR (CAR-Ts or CAR-NKs), and methods of using the CAR-Ts or CAR-NKs to treat a disease associated with the expression of FOLR1 thereof are described. Humanized anti-FOLR1 monoclonal antibodies and antigen-binding fragments thereof are also described.
    Type: Application
    Filed: April 7, 2020
    Publication date: May 26, 2022
    Inventors: Minghan Wang, Hui Zou, Haiqun Jia
  • Patent number: 11306151
    Abstract: Anti-TIP-1 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: April 19, 2022
    Assignee: Phanes Therapeutics, Inc.
    Inventors: Minghan Wang, Hui Zou, Joshua Oaks
  • Patent number: 11299550
    Abstract: Anti-CD73 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: April 12, 2022
    Assignee: Phanes Therapeutics, Inc.
    Inventors: Minghan Wang, Hui Zou, Fen Pei
  • Patent number: 11214615
    Abstract: Anti-TIM-3 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, an inflammatory disease, an autoimmune disease, a metabolic disease, and/or infectious diseases.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: January 4, 2022
    Assignee: Phanes Therapeutics, Inc.
    Inventors: Minghan Wang, Hui Zou
  • Publication number: 20210047399
    Abstract: Anti-DLL3 antibodies and antigen-binding fragments thereof, anti-CD47 antibodies and antigen-binding fragments thereof, and anti-CD47/DLL3 bispecific antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases, such as cancer and/or associated complications.
    Type: Application
    Filed: April 30, 2019
    Publication date: February 18, 2021
    Inventors: Minghan WANG, Hui ZOU, Haiqun JIA
  • Publication number: 20210032331
    Abstract: Anti-LAG-3 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, an inflammatory disease, an autoimmune disease, type 1 diabetes, and/or infectious diseases.
    Type: Application
    Filed: August 28, 2018
    Publication date: February 4, 2021
    Inventors: Minghan WANG, Hui ZOU, Haiqun JIA
  • Publication number: 20210032330
    Abstract: Anti-TIM-3 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, an inflammatory disease, an autoimmune disease, a metabolic disease, and/or infectious diseases.
    Type: Application
    Filed: July 26, 2018
    Publication date: February 4, 2021
    Inventors: Minghan WANG, Hui ZOU
  • Publication number: 20210002363
    Abstract: Anti-FOLR1 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.
    Type: Application
    Filed: March 7, 2019
    Publication date: January 7, 2021
    Inventors: Minghan WANG, Hui ZOU, Haiqun JIA
  • Publication number: 20200399396
    Abstract: Anti-TIP-1 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.
    Type: Application
    Filed: March 6, 2019
    Publication date: December 24, 2020
    Inventors: Minghan Wang, Hui Zou, Joshua Oaks
  • Publication number: 20200399364
    Abstract: Anti-CLDN18.2 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer and/or an inflammatory disease.
    Type: Application
    Filed: March 6, 2019
    Publication date: December 24, 2020
    Inventors: Minghan WANG, Hui ZOU, Haiqun JIA
  • Publication number: 20200399389
    Abstract: Anti-CD73 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer.
    Type: Application
    Filed: March 5, 2019
    Publication date: December 24, 2020
    Inventors: Minghan WANG, Hui ZOU, Fen PEI
  • Publication number: 20200362021
    Abstract: Anti-apelin antibodies and antigen-binding fragments thereof are described.
    Type: Application
    Filed: August 21, 2018
    Publication date: November 19, 2020
    Inventors: Minghan WANG, Hui ZOU, Arvin TAM
  • Publication number: 20200207853
    Abstract: Anti-CD47 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, inflammatory disease, infectious disease, atherosclerosis, cardiovascular disease, metabolic disease, radiation-induced injury, and/or autoimmune disease.
    Type: Application
    Filed: July 30, 2018
    Publication date: July 2, 2020
    Inventors: Minghan WANG, Hui ZOU, Joshua OAKS, Haiqun JIA
  • Patent number: 9493554
    Abstract: This disclosure relates to apelin antigen-binding proteins and methods of using the apelin antigen-binding proteins. The antigen-binding protein may comprise an antibody to apelin and can be used to treat pathological conditions involving angiogenesis. The pathological conditions can comprise cancer or retinopathy and/or retinopathy-related complications.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: November 15, 2016
    Assignee: AMGEN INC.
    Inventors: Shu-Chen Lu, Minghan Wang
  • Publication number: 20160053000
    Abstract: This disclosure relates to apelin antigen-binding proteins and methods of using the apelin antigen-binding proteins. The antigen-binding protein may comprise an antibody to apelin and can be used to treat pathological conditions involving angiogenesis. The pathological conditions can comprise cancer or retinopathy and/or retinopathy-related complications.
    Type: Application
    Filed: August 28, 2015
    Publication date: February 25, 2016
    Applicant: AMGEN INC.
    Inventors: Shu-Chen LU, Minghan WANG